Exalpha Biologicals, Inc.

Product Highlight

FIX&PERM Cell Fixation and Permeabilization Kit

Flow cytometric analyses with monoclonal antibodies were so far mainly restricted to cell surface molecules. Intracellular structures such as cytoplasmic or nuclear enzymes, oncoproteins, cytokines, immunoglobulins etc. were largely excluded from such studies. Also excluded from flow cytometric studies were cytoplasmic localizations of well-established membrane molecules like CD3 and CD22, which, in their cytoplasmic form, are the most reliable lineage markers in undifferentiated leukemia. With the FIX&PERM® Kit flow cytometric analysis of intracellular antigens has become as easy as surface antigen studies. The only prerequisite is the availability of suitable antibody conjugates. Most of the available monoclonal antibody conjugates can be used with the FIX&PERM® Kit, some determinants are sensitive, however, to the fixation step involved. This and the optimal fixation time have to be tested for each reagent.

News

Welcome, Peter Rutten

We are pleased to announce that Peter Rutten has now started in his role as Operations Director here at Exalpha Biologicals Inc. Peter has a Master’s of Science degree in Industrial and Organizational Psychology and this has lead him down a very business orientated career path. Peter is looking forward to working with the team at Exalpha. Peters primary focus is the customer experience and he will be working with the Laboratory team, the Quality Control team and the Order Processing team to ensure this focus is achieved. We all wish Peter well in his new role.

Exalpha Biologicals, Inc.

CD54 PE

  • Product Code: 0544
  • Size: 100 Tests
  • Availability: In Stock In Stock
  • Price (USD): $191

Cat #

0544		 Quantity:      

Data Sheet

Product Name

CD54 PE

Synonyms

CD54 PE

Host/Source

Mouse

Clone

D3.6

Isotype

IgG2b

Product Type

Single-Color Reagent

Reactivity

Human

Applications

Flow Cytometry

Purification

Protein A/G Chromatography

Size

100 Tests

Price (USD)

$191

Background

CD54, M.W. 90,000, antigen is the Intercellular Adhesion Molecule-1 (ICAM-1) and is the ligand for LFA-1 mediated adhesion. CD54 is weakly expressed on peripheral blood leukocytes. Upon activation the antigen is expressed strongly on B cells, T cells, macrophages and granulocytes. ICAM-1 is also inducible on endothelial cells, epithelial cells and fibroblasts.

Immunogen

CD54=Derived from the hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immunized with the major histocompatibility complex (MHC) class II-negative human b-lymphoblastoid cell line 6.16c13

Formulation

Provided as sterile filtered solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein

Customer Storage

Product should be stored at 4-8°C. DO NOT FREEZE

Product Image

Image Legend

Peripheral blood lymphocytes stained with Exalpha?s CD54 PE Conjugated Antibody (Cat. No. 0544).

Database Links:

SwissProtP05362Human

References

1. ICAM-1 a ligand for LFA-1 dependent adhesion of B,T and myeloid cells. Makgoba, M.W., Sanders, M.E., Ginther, Luce, G.E., Dustin, M.L., Springer,T.A., Clark, E.A., Mannoni, P., Shaw, S., Nature, 1988:331:86.

2. Supergene families meet in the immune system. Dustin, M.L., Staunton, D.E., and Springer, T.A., Immunol. Today. 1988:9:213.

3. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Staunto, D.E., Dustin, M.L., and Springer, T.A., Nature. 1989:339:61.

4. Leukocytes adhesion to cells. Molecular basis, Physiological Relevance and Abnormalities. Patarroyo, M., and Makgoba, M.W., Scand. J. Immunol. 1989;30:129.

5. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Marlin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber, W., and Merluzzi, V.J., Nature. 1990;44:70.


Product Specific References


This product has been used in:

1. Arpinati, M., et al, 'Use of anti-BDCA-2 antibody for detection of dendritic cells type-2 (DC2) in allogeneic hematopoietic stem cell transplantation' Bone Marrow Transplantation 2002, 29, , 887-891